High Heated Humidity in Stem Cell Transplant
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Airvo, Standard of Care.
- Who it may be relevant to
- Registry conditions: Autologous Stem Cell Transplant. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Canada
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Using Highly Heated Humidification to Minimize Aerodigestive Tract Complications of Autologous Stem Cell Transplant
Overview
The purpose of this study is to find out what effects of high heated humidity has on you and your mucositis.
Detailed description
This is a open label, case-control randomized, phase II clinical trial comparing the use of High Heated Humidity (H3) delivered using the Airvo 2 device to standard of care in Hematologic cancer recipients of autologous stem cell transplant (including Hodgkin lymphoma, non-Hodgkin lymphoma, and multiple myeloma).
Mucositis and aerodigestive tract complications are common across most types of cytotoxic chemotherapies. These complications are both more frequent and severe in recipients of high dose chemotherapy (HDT) and autologous stem cell transplant (ASCT). By extending the use of H3 to include the HDT/ASCT population, there is the possibility to decrease or minimize the complications associated with the current standard treatment process. Shorter, less complicated hospital stays could results for those whose course would otherwise end up being longer due to complications/set- backs. The length of time to use the device per day is a minimum of 4 hours/day up to approximately 14 days while being an inpatient. Treatment beyond 14 days is exceptional and will be done only in those individuals who continue to have mucositis beyond 14 days. In this case, patients may receive treatment up to 30 days.
Interventions
- Device Airvo
Fisher \& Paykel's AIRVO 2 is a humidifier with integrated flow generator that delivers high flow warmed and humidified respiratory gases to spontaneously breathing patients through a variety of interfaces including nasal cannula. Flow can be delivered from 2 to 60 LPM - Other Standard of Care
The standard of care for mucositis at the Cross Cancer institute involves supportive therapies including oral hydration (water or wet sponges) or medicated mouthwashes.
Primary outcome measures
- Mucositis severity symptoms [Time frame: During treatment (up to 30 days)]
- Mucositis severity assessment [Time frame: During treatment (up to 30 days)]
Secondary outcome measures (5)
- Febrile Neutropenia [Time frame: During treatment (up to 30 days)]
- Nosocomial infections [Time frame: During treatment (up to 30 days)]
- Length of stay to be changed in hospital [Time frame: During treatment (up to 30 days)]
- Dietary pattern/intake [Time frame: During treatment (up to 30 days)]
- Patient weight [Time frame: The comparison will be weight at admission vs weight at discharge (Day 14 or Day 30)]
Eligibility criteria
Inclusion criteria
- Minimum 18 years of age
- Have given written consent prior to any study-specific procedures or have had an acceptable individual capable of giving consent on the patient's behalf.
- Have one of non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma and found to require high-dose, melphalan-based chemotherapy and autologous stem cell transplant (ASCT) as part of standard of care treatment (includes patients receiving ASCT also requiring oxygen).
- Performance status of ECOG 0-2
- Are reliable and willing to make themselves available for the duration of the study, and are willing to follow study procedures.
Exclusion criteria
- Nasal blockage such as nasal polyps, deviated septum or nasal packing would either not allow the proper flow of heated humidity into the nares or it would be too uncomfortable to tolerate during the intervention.
- Those with influenza like illness. The intervention is not in itself, an aerosol generating medical device. However, if influenza positive, there could be airborne spread of the virus impacting both staff and other patients.
- Tracheostomy Tube Patients would require a different type of equipment attachment which is not included in this study. Tracheostomy tubes by-pass the upper airway and therefore the intervention cannot be used for the purpose of assessing mucositis. This intervention is used regularly on tracheostomy patients with good success however in this case, the upper airway is by-passed and therefore there would be no impact on mucositis.
- Patients with significant co-morbidities that would prevent compliance of equipment use as determined by the treating physician.
- Patients who have Obstructive Sleep Apnea who use a CPAP machine at night. This population would not be able to use the intervention concurrently with the CPAP device as both utilize the nares.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Canada · 1 center
- Cross Cancer Institute — Edmonton
Identifiers
NCT: NCT05358262 · IIT-0017